Emerging
Launch
Scale
Sustain
Expansion
Life sciences companies face new financial and operational challenges as they bring their products to market for the first time. Navigating income taxation and research and development tax credits, is key to maximizing returns, managing risk, and ensuring regulatory compliance, while positioning for long-term growth and profitability.
Cloud-based financial management and accounting: Sage Intacct
Enterprise resource planning: IFS
Life sciences compliance solutions: complianceNOW
Drug price transparency
Global spend transparency reporting: transparencyNOW
Enterprise risk management
Digital consulting
Specialty tax
Launch
Emerging
Life sciences organizations amid clinical development and raising capital regularly face complex regulatory, risk and financial landscapes. Ensure compliance while improving operational efficiency to reduce costs and enhance productivity, allowing you to focus on innovation. Safeguard your launch and valuation with our robust enterprise risk management (ERM), internal audit and System and Organization Controls (SOCs) services.
Baker Tilly Advantage for BioTech and MedTech companies
Assurance
Cloud-based financial management and accounting: Sage Intacct
Government and commercial pricing & contracting
Enterprise risk management
Specialty tax
Exit
Prepare for exit
Once companies begin generating revenue from their product, companies must scale operations, optimize production processes, and manage supply chain risks, to meet demand sustain growth. Enhancing efficiency, controlling costs and ensuring compliance are essential for success in the competitive market.
Specialty tax
Digital consulting
Scale back-office functions: Oracle Jumpstart
scale
At any stage, companies may begin evaluating opportunities for an exit, whether through a sale, merger, or licensing agreement. Accurate valuation is critical to securing favorable terms and maximizing returns. Proper preperation including financial assessments, risk management and strategic guidance helps ensure companies are well-positioned to capitalize on these opportunities.
Valuations
Enterprise risk management
Sell side commercial due diligence
Prepare for Exit
As life sciences companies confront patent expirations and increased competition from generics, reinvesting in the business is essential to maintaining market position. Streamlining ethics and compliance programs can improve operational efficiency and ensure regulatory adherence. Additionally, companies may turn to staffing solutions or outsourcing non-core functions to reduce costs and concentrate on strategic initiatives.
Enterprise risk management
Compliance and ethics
AI
Scale back-office functions: Oracle Jumpstart
Sustain
As life sciences companies expand through new products, label extensions or enter global markets, they encounter increasingly complex challenges. Engaging with healthcare professionals (HCPs) becomes more intricate, while complying with evolving regulations and transparency obligations becomes more demanding Successfully navigating these complexities is key to driving continued growth and market success.
Third-party risk management and due diligence
End-to-end HCP engagement: engagementNOW
Global spend transparency reporting: transparencyNOW
Managed care advisory
Expansion